HJB647 low dose

Phase 1Small molecule

Novartis

HJB647 low dose is one of 25 small molecule programs targeting Heart Failure. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Heart Failure With Reduced Ejection FractionRecruiting

Heart FailurePhase 1

Active, not recruiting

Heart Failure With Reduced Ejection FractionPhase 1

Recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Brethine

Sanofi

Preclinical

1 2

Amidate

Pfizer

Preclinical

1 3

LCZ696

Novartis

Preclinical

15 4

Zemplar

AbbVie

Preclinical

—5

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Zoloft

VViatris Specialty LLC

Preclinical

2 7

Xifaxan

SSalix

Preclinical

2 8

Coumadin

AAbbott

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

GLP-1

RRigshospitalet, Denmark

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Heart Failure With Reduced Ejection Fraction

NCT07465653

Clinical

Trials by Indication[1]

Heart Failure With Reduced Ejection Fraction1 trial

A Multi-center, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of HJB647 in Participants With Chronic Stable Heart Failure With Reduced Ejection Fraction

Recruiting· Novartis logo

Novartis·Phase 1·NCT07465653·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HJB647 low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HJB647 low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HJB647 low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novartis

HJB647 low dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Heart Failure With Reduced Ejection Fraction1 trial

References

Drug Info

Quick Facts

Related News